2-(benzylamino-methyl)-2,3,7,9-tetrahydro-[1,4]dioxino[2,3-e]indol-8-one | 189683-28-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并二恶烷
• 英文名称: 2-(benzylamino-methyl)-2,3,7,9-tetrahydro-[1,4]dioxino[2,3-e]indol-8-one
• 英文别名: 2-(Benzylamino-methyl)-2,3,8,9-tetrahydro-7H-4-dioxino[2,3-e]indol-8-one；2-(benzylamino-methyl)-2,3,8,9-tetrahydro-7H-1,4-dioxino[2,3-e]indol-8-one；2-((Benzylamino)methyl)-2,3-dihydro-7H-[1,4]dioxino[2,3-e]indol-8(9H)-one；2-[(benzylamino)methyl]-2,3,7,9-tetrahydro-[1,4]dioxino[2,3-e]indol-8-one
• CAS: 189683-28-1
• 化学式: C₁₈H₁₈N₂O₃
• 分子量: 310.353
• InChiKey: DYJIKHYBKVODAC-UHFFFAOYSA-N

物化性质

• 沸点：
  511.7±50.0 °C(Predicted)
• 密度：
  1.256±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  23
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.28
• 拓扑面积：
  59.6
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  methyl 2-(3-((benzylamino)methyl)-6-nitro-2,3-dihydrobenzo[b][1,4]dioxin-5-yl)acetate 在 氧化铂 、 氢气 、 乙醇乙酸乙酯 、 crude material 、 乙醇 、 盐酸 、 silica gel 、 methanol-dichloromethane 作用下， 以 乙醇乙酸乙酯 为溶剂， 反应 32.0h， 以The title product was isolated in 22% yield的产率得到2-(benzylamino-methyl)-2,3,7,9-tetrahydro-[1,4]dioxino[2,3-e]indol-8-one
  参考文献：
  名称：

  Oxindoledioxans, synthesis thereof, and intermediates thereto

  摘要：

  本发明提供了制备具有多巴胺自主受体激动剂活性和部分多巴胺D2受体后突触激动剂活性的化合物的方法。这些化合物可用于治疗多巴胺能紊乱疾病，如精神分裂症、情感性精神障碍、帕金森病、抽动症、高催乳素血症和药物成瘾等。

  公开号：

  US20070293686A1

文献信息

• Aminomethyl-2 3 8 9-tetrahydro-7H-1 4-dioxino\x9b2 3-E!-indol-8-ones and
  申请人：American Home Products Corporation

  公开号：US05756532A1

  公开（公告）日：1998-05-26

  The compounds of formula I: ##STR1## wherein R.sup.1 and R.sup.2 are, independently, hydrogen, alkyl, phenyl or benzyl; or R.sup.1 and R.sup.2, taken together, are benzylidene optionally substituted with R.sup.3 as defined below or alkylidene, or R.sup.1 and R.sup.2, taken together with the carbon to which they are attached, form a carbonyl moiety or a cycloalkyl group; R.sup.3 is hydrogen, hydroxy, halo, trifluoromethyl, trifluoromethoxy, alkyl, alkoxy, aralkoxy, alkanoyloxy, amino, mono- or di-alkylamino, alkanamido or alkanesulfonamido; R.sup.4 is hydrogen or alkyl; m is an integer 0, 1 or 2; n is an integer from 0 to 6, inclusive; Z is hydrogen, hydroxy, alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, polycyclo-alkyl, phenyl optionally substituted with R.sup.3 as defined above, phenoxy optionally substituted with R.sup.3 as defined above, naphthyl optionally substituted with R.sup.3 as defined above or naphthyloxy optionally substituted with R.sup.3 as defined above, heteroaryl or heteroaryloxy, in which the heterocyclic ring of the heteroaryl or heteroaryloxy group is selected from thiophene, furan, pyridine, pyrazine, pyrimidine, indole, indazole, imidazole, chroman, coumarin, carbostyril, quinoline, benzisoxazole, benzoxazole, pyrazole, pyrrole, thiazole, oxazole, or isoxazole and the heterocyclic ring is optionally substituted by R.sup.3 as defined above; or a pharmaceutically acceptable salt thereof, are useful in treating disorders of the dopaminergic system.

  式I的化合物：其中R.sup.1和R.sup.2分别是氢、烷基、苯基或苄基；或R.sup.1和R.sup.2一起是苄基亦可选择性地用如下定义的R.sup.3取代或烷基亦可选择性地用如下定义的R.sup.3取代，或R.sup.1和R.sup.2与它们附着的碳一起形成一个羰基或环烷基；R.sup.3是氢、羟基、卤素、三氟甲基、三氟甲氧基、烷基、烷氧基、芳基氧基、烷酰氧基、氨基、单烷基或双烷基氨基、烷酰胺基或烷磺酰胺基；R.sup.4是氢或烷基；m是整数0、1或2；n是整数0至6之间的整数；Z是氢、羟基、烷基、烯基、炔基、烷氧基、环烷基、多环烷基、苯基亦可选择性地用如上定义的R.sup.3取代、苯氧基亦可选择性地用如上定义的R.sup.3取代、萘基亦可选择性地用如上定义的R.sup.3取代或萘氧基亦可选择性地用如上定义的R.sup.3取代、杂环芳基或杂环芳氧基，其中杂环芳基或杂环芳氧基的杂环环由噻吩、呋喃、吡啶、吡嗪、嘧啶、吲哚、吲唑、咪唑、色苷、香豆素、喹啉、苯并异噁唑、苯并噁唑、吡唑、吡咯、噻唑、噁唑或异噁唑组成，并且该杂环环可以选择性地用如上定义的R.sup.3取代；或者其药学上可接受的盐，用于治疗多巴胺系统疾病。
• SEROTONERGIC AGENTS FOR TREATING SEXUAL DYSFUNCTION
  申请人：SUKOFF RIZZO J. Stacey

  公开号：US20080070925A1

  公开（公告）日：2008-03-20

  Methods and compositions are provided for treating sexual dysfunction, e.g., sexual dysfunction associated with drug treatment, using 5-HT 1A receptor antagonists.

  提供了用于治疗性功能障碍（例如与药物治疗有关的性功能障碍）的方法和组合物，使用5-HT1A受体拮抗剂。
• Serotonergic agents for treating sexual dysfunction
  申请人：Sukoff Rizzo J. Stacey

  公开号：US20060287335A1

  公开（公告）日：2006-12-21

  Methods and compositions are provided for treating sexual dysfunction, e.g., sexual dysfunction associated with drug treatment, using 5-HT 1A receptor antagonists.

  提供了一种治疗性功能障碍的方法和组合物，例如与药物治疗相关的性功能障碍，使用5-HT1A受体拮抗剂。
• Aminomethyl-2,3,8,9-tetrahydro-7H-1,4-dioxino-\x9b2,3-e!-indol-8-ones and
  申请人：American Home Products Corporation

  公开号：US05962465A1

  公开（公告）日：1999-10-05

  The compounds of formula I: ##STR1## wherein R.sup.1 and R.sup.2 are, independently, hydrogen, alkyl, phenyl or benzyl; or R.sup.1 and R.sup.2, taken together, are benzylidene optionally substituted with R.sup.3 as defined below or alkylidene, or R.sup.1 and R.sup.2, taken together with the carbon to which they are attached, form a carbonyl moiety or a cycloalkyl group; R.sup.3 is hydrogen, hydroxy, halo, trifluoromethyl, trifluoromethoxy, alkyl, alkoxy, aralkoxy, alkanoyloxy, amino, mono- or di-alkylamino, alkanamido or alkanesulfonamido; R.sup.4 is hydrogen or alkyl; m is an integer 0, 1 or 2; n is an integer from 0 to 6, inclusive; Z is hydrogen, hydroxy, alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, polycyclo-alkyl, phenyl optionally substituted with R.sup.3 as defined above, phenoxy optionally substituted with R.sup.3 as defined above, naphthyl optionally substituted with R.sup.3 as defined above or naphthyloxy optionally substituted with R.sup.3 as defined above, heteroaryl or heteroaryloxy, in which the heterocyclic ring of the heteroaryl or heteroaryloxy group is selected from thiophene, furan, pyridine, pyrazine, pyrimidine, indole, indazole, imidazole, chroman, coumarin, carbostyril, quinoline, benzisoxazole, benzoxazole, pyrazole, pyrrole, thiazole, oxazole, or isoxazole and the heterocyclic ring is optionally substituted by R.sup.3 as defined above; or a pharmaceutically acceptable salt thereof, are useful in treating disorders of the dopaminergic system.

  化学式为I的化合物：##STR1## 其中R.sup.1和R.sup.2分别为氢、烷基、苯基或苄基；或R.sup.1和R.sup.2连在一起，是苄基亚甲基，可选地用下面定义的R.sup.3取代，或烷基亚甲基，或R.sup.1和R.sup.2与它们连接的碳形成羰基基团或环烷基；R.sup.3为氢、羟基、卤素、三氟甲基、三氟甲氧基、烷基、烷氧基、芳基氧基、烷酰氧基、氨基、单烷基或二烷基氨基、烷基酰胺或烷基磺酰胺；R.sup.4为氢或烷基；m为0、1或2的整数；n为0到6的整数，包括0和6；Z为氢、羟基、烷基、烯基、炔基、烷氧基、环烷基、多环环烷基、苯基（可选地用上述定义的R.sup.3取代）、苯氧基（可选地用上述定义的R.sup.3取代）、萘基（可选地用上述定义的R.sup.3取代）或萘氧基（可选地用上述定义的R.sup.3取代）、杂环芳基或杂环芳基氧基，其中杂环芳基或杂环芳基氧基的杂环环选自噻吩、呋喃、吡啶、吡嗪、嘧啶、吲哚、吲唑、咪唑、色甘醇、香豆素、喹啉、苯并异噁唑、苯并噁唑、吡唑、吡咯、噻唑、噁唑或异噁唑，且杂环环可选地由上述定义的R.sup.3取代；或其药学上可接受的盐，适用于治疗多巴胺系统疾病。
• COMPOUNDS AND PROCESSES FOR PREPARING SUBSTITUTED AMINOMETHYL-2,3,8,9-TETRAHYDRO-7H-1,4-DIOXINO[2,3-e]INDOL-8-ONES
  申请人：Wang Zhe-qing

  公开号：US20100217012A1

  公开（公告）日：2010-08-26

  Processes and intermediates are provided for the preparation of substituted aminomethyl 2,3,8,9-tetrahydiO-7H-1,4-dioxino[2.3-e]indo]-8-ones of the Formula (A) wherein the variables n, R and R 3 are as described herein. Such compounds are useful, for example, as dopamine receptor agonists.

  提供了制备取代氨甲基2,3,8,9-四氢O-7H-1,4-二氧杂[2.3-e]吲哚-8-酮（式（A））的过程和中间体，其中变量n，R和R3如本文所述。例如，这些化合物可用作多巴胺受体激动剂。